Production of monoclonal antibody to quantify serum CA125 concentration in breast and ovarian cancer patients
Authors
DOI: https://doi.org/10.15625/2615-9023/v42n4.15095Keywords:
CA-125, breast cancer, ELISA, ovarian cancer, monoclonal antibodies.References
Bast R. C., Jr., Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L., Zurawski V. R., Jr., Knapp R. C., 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309: 883–887.
Birgen D., Ertem U., Duru F., Sahin G., Yuksek N., Bozkurt C., Karacan C. D., Aksoy C., 2005. Serum Ca 125 levels in children with acute leukemia and lymphoma. Leuk Lymphoma, 46: 1177–1181.
Bottoni P., Scatena R., 2015. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol, 867: 229–244.
Coward J. I., Middleton K., Murphy F., 2015. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health, 7: 189–203.
Cramer D. W., Vitonis A. F., Welch W. R., Terry K. L., Goodman A., Rueda B. R., Berkowitz R. S., 2010. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol, 119: 462–468.
Felder M., Kapur A., Gonzalez-Bosquet J., Horibata S., Heintz J., Albrecht R., Fass L., Kaur J., Hu K., Shojaei H., Whelan R. J., Patankar M. S., 2014. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer, 13: 129.
Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M. D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T. R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B. A., Gayther S. A., Zelada-Hedman M., 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet, 62: 676–689.
Gaetje R., Winnekendonk D. W., Ahr A., Kaufmann M., 2002. Ovarian cancer antigen CA 125 influences adhesion of human and mammalian cell lines in vitro. Clin Exp Obstet Gynecol, 29: 34–36.
Kohler G., Milstein C., 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256: 495–497.
Kohler G., Milstein C., 1992. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. Biotechnology, 24: 524–526.
Libson S., Lippman M., 2014. A review of clinical aspects of breast cancer. Int Rev Psychiatry, 26: 4–15.
McIntosh M. W., Drescher C., Karlan B., Scholler N., Urban N., Hellstrom K. E., Hellstrom I., 2004. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol, 95: 9–15.
O'Brien T. J., Beard J. B., Underwood L. J., Dennis R. A., Santin A. D., York L., 2001. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol, 22: 348–366.
Reinartz S., Failer S., Schuell T., Wagner U., 2012. CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer, 48: 1558–1569.
Senapati S., Das S., Batra S. K., 2010. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci, 35: 236–245.
Vasen H. F., Tesfay E., Boonstra H., Mourits M. J., Rutgers E., Verheyen R., Oosterwijk J., Beex L., 2005. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer, 41: 549–554.
Yoo E. M., Chintalacharuvu K. R., Penichet M. L., Morrison S. L., 2002. Myeloma expression systems. J Immunol Methods, 261: 1–20.
Zhao S., Mei Y., Wang J., Zhang K., Ma R., 2016. Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge. PLoS One, 11: e0157639.
Downloads
Metrics
Downloads
PDF Downloaded: 169